Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2013-05-03 Director's Dealing
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2013-05-03 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated April 26, 2013, by Galena Biopharma, Inc. The key content is the appointment of a new director, William L. Ashton, to the board, including details about his stock option grant and terms. There is no financial data or earnings information, nor is it an annual or quarterly report. The primary focus is on a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3620 characters, which is consistent with a typical 8-K filing for management changes. Therefore, the correct classification is MANG with high confidence.
2013-05-02 English
PRIMARY DOCUMENT
Director's Dealing
2013-05-01 English
PRIMARY DOCUMENT
Director's Dealing
2013-05-01 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about the upcoming annual stockholders meeting, voting instructions, proposals to be voted on, and how to obtain the full proxy materials. The document explicitly states it is "Definitive Additional Materials" related to the proxy statement and provides instructions for accessing the full proxy materials online or requesting paper copies. It does not contain the full proxy statement itself, nor detailed financial data or management discussion. It is essentially an announcement and overview of proxy materials for the annual meeting, not the proxy statement or annual report itself. Therefore, it fits best under Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2013-04-29 English
DEF14A
Proxy Solicitation & Information Statement
2013-04-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.